Retrospective analysis of long‐term survival factors in patients with advanced non‐small cell lung cancer treated with nivolumab

BACKGROUND: Nivolumab, an immune checkpoint inhibitor (ICI), has changed the treatment paradigm for advanced non‐small cell lung cancer (NSCLC). However, factors associated with long‐term survival in NSCLC patients treated with ICIs remain unknown. This study aimed to evaluate patient characteristic...

Descripción completa

Detalles Bibliográficos
Autores principales: Murakami, Yusuke, Tamiya, Akihiro, Taniguchi, Yoshihiko, Adachi, Yuichi, Enomoto, Takatoshi, Azuma, Koji, Inagaki, Yuji, Kouno, Shunichi, Matsuda, Yoshinobu, Okishio, Kyoichi, Atagi, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841702/
https://www.ncbi.nlm.nih.gov/pubmed/34989133
http://dx.doi.org/10.1111/1759-7714.14303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841702/
https://www.ncbi.nlm.nih.gov/pubmed/34989133
http://dx.doi.org/10.1111/1759-7714.14303

Ejemplares similares